Tonix Pharmaceuticals (TNXP)
NASDAQ:TNXP
Top Page
Tonix Pharma
(NASDAQ:TNXP)
Select Model
Select Model
Rating:44Neutral
Price Target:
$11.50
▼(-23.74% Downside)
Action:ReiteratedDate:04/01/26
The score is held down primarily by weak financial performance (large ongoing operating losses and persistent cash burn) and bearish technicals (below key moving averages with negative MACD). Positive corporate events provide support via encouraging clinical/pipeline progress and the Nasdaq uplisting, but valuation remains constrained by negative earnings and no dividend.
Positive Factors
Conservative balance sheet, low leverage
A materially stronger capital base and very low debt improve Tonix's financial flexibility to fund clinical programs and absorb trial setbacks without immediate insolvency risk. This reduces near-term refinancing urgency and interest burden, supporting multi-quarter development timelines and strategic optionality.
Negative Factors
Large, persistent negative cash flow
Consistently large negative operating and free cash flows indicate the company burns meaningful cash each year to fund R&D and operations. This structural cash deficit creates recurring dependence on external financing, heightens dilution risk, and could force program prioritization or delays if capital access tightens.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet, low leverage
A materially stronger capital base and very low debt improve Tonix's financial flexibility to fund clinical programs and absorb trial setbacks without immediate insolvency risk. This reduces near-term refinancing urgency and interest burden, supporting multi-quarter development timelines and strategic optionality.
Read all positive factors
Tonix Pharma (TNXP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$174.00M
Dividend YieldN/A
Average Volume (3M)420.00K
Price to Earnings (P/E)―
Beta (1Y)1.42
Revenue Growth-8.79%
EPS Growth81.36%
CountryUS
Employees81
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.98
Shares Outstanding13,405,401
10 Day Avg. Volume401,622
30 Day Avg. Volume420,002
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.54
Price to Sales (P/S)10.14
P/FCF Ratio-1.29
Enterprise Value/Market Cap-0.16
Enterprise Value/Revenue-2.09
Enterprise Value/Gross Profit-4.23
Enterprise Value/Ebitda0.22
Forecast
1Y Price Target
$51.00Price Target Upside238.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-9.28
Revenue Forecast (FY)$89.70M
Tonix Pharma Business Overview & Revenue Model
Company Description
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio in...
How the Company Makes Money
Tonix primarily seeks to generate future revenue by advancing internally developed or in-licensed product candidates through clinical development toward regulatory approval and commercialization. Until it has approved products, its revenue model t...
Tonix Pharma Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
63
Positive
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 13.11M | 10.09M | 7.77M | 0.00 | 0.00 |
| Gross Profit | 6.47M | 2.33M | 3.03M | 0.00 | 0.00 |
| EBITDA | -123.78M | -74.32M | -114.09M | -110.84M | -92.26M |
| Net Income | -124.02M | -130.04M | -116.66M | -110.22M | -92.29M |
Balance Sheet | |||||
| Total Assets | 277.17M | 162.89M | 154.46M | 225.69M | 240.90M |
| Cash, Cash Equivalents and Short-Term Investments | 207.64M | 98.78M | 24.95M | 120.23M | 178.66M |
| Total Debt | 1.31M | 5.30M | 9.81M | 760.00K | 956.00K |
| Total Liabilities | 32.02M | 23.33M | 48.93M | 18.51M | 22.18M |
| Stockholders Equity | 245.15M | 139.56M | 105.53M | 207.18M | 218.72M |
Cash Flow | |||||
| Free Cash Flow | -103.21M | -61.05M | -109.90M | -146.20M | -110.86M |
| Operating Cash Flow | -99.84M | -60.92M | -102.00M | -98.05M | -75.56M |
| Investing Cash Flow | -4.53M | -120.00K | -29.07M | -48.15M | -35.31M |
| Financing Cash Flow | 214.53M | 134.87M | 36.52M | 87.84M | 212.49M |
Tonix Pharma Technical Analysis
Neutral
15.08
Price Trends
14.42
Negative
15.74
Negative
23.42
Negative
Market Momentum
-0.44
Positive
46.72
Neutral
33.13
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TNXP, the sentiment is Neutral. The current price of 15.08 is above the 20-day moving average (MA) of 13.89, above the 50-day MA of 14.42, and below the 200-day MA of 23.42, indicating a bearish trend. The MACD of -0.44 indicates Positive momentum. The RSI at 46.72 is Neutral, neither overbought nor oversold. The STOCH value of 33.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TNXP.
Tonix Pharma Risk Analysis
Tonix Pharma disclosed 66 risk factors in its most recent earnings report. Tonix Pharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tonix Pharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $184.51M | -21.41 | -13.46% | ― | 35.42% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $152.31M | -0.86 | -55.02% | ― | -46.92% | 20.26% | |
49 Neutral | $132.28M | -2.82 | 593.93% | ― | -75.77% | -31.24% | |
48 Neutral | $424.90M | -40.48 | -110.72% | ― | ― | 77.08% | |
47 Neutral | $304.00M | -3.11 | -77.91% | ― | -76.59% | 94.03% | |
44 Neutral | $174.00M | -0.71 | -60.15% | ― | -8.79% | 81.36% |
* Healthcare Sector Average
TNXP
Tonix Pharma
13.35
-3.65
-21.47%
PLX
Protalix
2.36
-0.26
-9.92%
FATE
Fate Therapeutics
1.34
0.22
19.64%
AVTX
Avalo Therapeutics
13.90
9.00
183.67%
FBRX
Forte Biosciences
32.42
26.58
455.14%
IPHA
Innate Pharma
1.63
-0.28
-14.66%
Tonix Pharma Corporate Events
Business Operations and StrategyProduct-Related Announcements
Tonix Pharma Advances TNX-4800 Lyme Disease Prevention Program
Positive
Mar 31, 2026
On March 31, 2026, Tonix Pharmaceuticals announced program updates for TNX-4800, its monoclonal antibody candidate for protection against Lyme disease, highlighting that Phase 1 data were presented on March 30, 2026, at the World Vaccine Congress ...
Business Operations and StrategyProduct-Related Announcements
Tonix Pharma Begins Phase 1 Study of TNX-1900
Positive
Mar 26, 2026
On March 26, 2026, Tonix Pharmaceuticals announced that the first participant was dosed in a Phase 1 investigator-initiated study of TNX-1900, its intranasal potentiated oxytocin candidate. The trial will assess the drug’s effect on trigemin...
Business Operations and StrategyProduct-Related Announcements
Tonix Pharma Highlights Positive Phase 3 Fibromyalgia Data
Positive
Mar 10, 2026
On March 10, 2026, Tonix Pharmaceuticals reported new clinical data on TONMYA (cyclobenzaprine HCl sublingual tablets) from two oral presentations at the 8th International Congress on Controversies in Fibromyalgia. The first presentation detailed ...
Business Operations and StrategyDelistings and Listing Changes
Tonix Pharma Uplists to Nasdaq Global Select Market
Positive
Mar 3, 2026
On March 3, 2026, Tonix Pharmaceuticals announced that Nasdaq approved the transfer of its common stock listing from the Nasdaq Capital Market to the Nasdaq Global Select Market, with trading on the higher-tier market commencing the same day under...
Financial DisclosuresRegulatory Filings and Compliance
Tonix Pharma Incorporates Prior Financial Information by Reference
Neutral
Feb 3, 2026
Tonix Pharma disclosed that the information related to its financial results or operations referenced in a specific filing section is being incorporated by reference into the current disclosure, without providing additional operational, strategic,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.